

IL17A, IL17F

Research Grade Bimekizumab

Catalog No.	DHH28803A DHH28803B	Quantity:	100 µg 1.0 mg
Alternate Names:	Interleukin-17A, IL-17A, CTLA-8,, Interleukin-17F, IL-17F, CDP4940, UCB-4940, UCB4940		
Description:	Bimekizumab is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-17F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines.		
Concentration:	1.0 mg/ml, lot specific		
UniProt ID (target):	Q16552, Q96PD4		
Source:	XtenCHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Bimekizumab		
Specificity:	Human IL-17A and Human IL-17F		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Formulation:	0.01M PBS, pH 7.4		
Purification:	Protein A/G affinity chromatography		
Purity:	> 95% as determined by SDS-PAGE		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com